8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 22, 2020)

Filed July 22, 2020For Securities:BIIB

Summary

Biogen Inc. filed an 8-K on July 22, 2020, to announce its second-quarter 2020 financial results. The key information is contained within a press release furnished as Exhibit 99.1, which provides details on the company's operational performance and financial condition for the period ending June 30, 2020. Investors should refer to this press release for specific financial metrics, revenue figures, profitability, and any forward-looking statements or business updates provided by the company. While the 8-K itself is brief and primarily serves as a vehicle to file the press release, the attached press release is the substantive document for understanding Biogen's performance during the second quarter. This includes any commentary on the drivers of financial results, updates on product sales (particularly for key drugs), and strategic developments that could impact future performance. It's important to note that this information is furnished and not deemed 'filed' for certain legal purposes, but it represents the company's official communication regarding its quarterly performance.

Key Highlights

  • 1Biogen Inc. announced its second-quarter 2020 financial results via a press release on July 22, 2020.
  • 2The 8-K filing primarily serves to furnish the press release containing the detailed financial and operational results.
  • 3Investors should consult Exhibit 99.1 (the press release) for specific Q2 2020 financial data.
  • 4The filing indicates no new material financial statements or exhibits beyond the press release and interactive data file.
  • 5The information provided is furnished under Item 2.02 and is not considered 'filed' for certain legal liabilities.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide investors with Biogen Inc.'s financial results for the second quarter ended June 30, 2020. The detailed information is contained within the furnished press release (Exhibit 99.1).

The specific financial details, including revenue, earnings, and other operational metrics for the second quarter of 2020, are available in the press release dated July 22, 2020, which is attached as Exhibit 99.1 to this 8-K filing.

This 8-K filing does not include new audited financial statements. The primary exhibit furnished is Biogen's press release announcing its quarterly results, along with an interactive data file.

When information is 'furnished' under Item 2.02, it means the company is providing it to the SEC but it is not subject to the same level of liability under Section 18 of the Securities Exchange Act of 1934 as if it were 'filed'. While it's still an official disclosure, investors should be aware of this distinction regarding legal implications.